Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
[PDF][PDF] Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - J Clin …, 2016 - researchgate.net
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2016 - europepmc.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
[PDF][PDF] Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - J Clin …, 2016 - clf1.medpagetoday.com
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
[PDF][PDF] Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - J Clin …, 2016 - scholar.archive.org
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
G Etienne, J Guilhot, D Rea… - Journal of clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Imatinib (IM) can safely be discontinued
in patients with chronic myeloid leukemia (CML) who have had undetectable minimal …
in patients with chronic myeloid leukemia (CML) who have had undetectable minimal …